Cytokinetics | CYTK - Cash And Equivalent


Cytokinetics reported $225.47M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Bayer EUR 5.9B 1.34B Sep/2025
Biogen USD 3.86B 1.1B Sep/2025
Bristol-Myers Squibb USD 15.73B 3.13B Sep/2025
Cytokinetics USD 225.47M 150.53M Sep/2025
Eisai JPY 285.38B 19.82B Jun/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
Exelixis USD 376.3M 211.87M Sep/2025
Geron USD 79.99M 389K Sep/2025
Halozyme Therapeutics USD 419.66M 357.8M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Ligand Pharmaceuticals USD 664.52M 596.85M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025